Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx is a growing but deeply loss-making rare-disease biotech at a fragile juncture. Topline momentum (revenue up 20.1% in FY2025 to $673M) and a newly approved gene therapy (DTX401) are real positives, but the September 2026 GTX-102 Phase 3 failure — the second Phase 3 miss in nine months — crushed the stock about 44% and forced a cost-reduction reassessment. The company runs a roughly $500M annual cash deficit, has negative book equity, about $1.2B of royalty-sale obligations against its Crysvita stream, roughly a 12-month cash runway, and no dividend. SEC filings show no going-concern statement, no debt covenants and a clean audit opinion, which argues against outright distress; still, weak and inconsistent financials with elevated binary and dilution risk warrant caution — a do-nothing profile until the pipeline and funding picture stabilize.

The dominant near-term driver is the 2026-09-02 Phase 3 Aspire failure for GTX-102/apazunersen in Angelman syndrome (announced, bearish, not priced in), which produced a determinate media-sentiment deterioration from a mildly positive baseline (polarity_score ≈ +0.13) to a strongly bearish scoring window (≈ -0.68) and a ~40–46% crash to a record low. Red-Flag Screen: no severe flags; moderate red-flag cap applied for conflicting catalyst signals — the regulator-confirmed DTX401 (genglycos) FDA approval is the offsetting bullish leg but was not rewarded by the tape, so the evidence reads as a weak, deteriorating setup rather than a balanced mix.

Bearish/broken structure. Price 14.85 is a record low after a -44.0% crash (GTX-102 Phase 3 Aspire failure announced post-close 2026-09-02). Price sits below every moving average: SMA20 25.57, SMA50 27.99, SMA200 26.08, EMA9 23.76, EMA21 25.30. ADX14 45.49 with price under all MAs reads as a strong DOWN trend (ADX is direction-agnostic). MACD line -1.23 is below signal -0.63 and below zero with a negative, widening histogram (-0.60). RSI14 19.10 and Williams %R -92.92 are deeply oversold, but in a broken structure that is bounce-risk only, not a reversal signal. Score 1.